SCHEMBL5722044

SCHEMBL5722044

O=C(Cc1ncc[nH]1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
AGTR1 P30556 2/20 0.45
KDM4E B2RXH2 1/20 0.45
KMO O15229 3/20 0.43
TSHR P16473 1/20 0.42
GAA P10253 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD11B1 P28845 1/20 0.40
MAOB P27338 1/20 0.40
MGAM O43451 1/20 0.40
AMY1A P0DUB6 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10363200 0.83 NPC1 (0.54) ALDH1A1KDM4EGAASMN1; SMN2TAAR1
SCHEMBL10514214 0.78 PTPN1 (0.50) ALDH1A1KDM4EGAASMN1; SMN2TAAR1
Hydrochloric Acid SCHEMBL11445748 0.77 PTPN1 (0.49) ALDH1A1KDM4EGAASMN1; SMN2TAAR1
SCHEMBL5093427 0.77 RAB9A (0.53) ALDH1A1KDM4EGAASMN1; SMN2HPGD
SCHEMBL10610629 0.77 FPR2 (0.56) ALDH1A1KDM4EGAASMN1; SMN2HPGD
SCHEMBL4968860 0.76 GAA (0.61) ALDH1A1KDM4EGAASMN1; SMN2TAAR1
SCHEMBL5523501 0.75 GAA (0.47) ALDH1A1KDM4EGAASMN1; SMN2TAAR1
SCHEMBL5091485 0.75 ALDH1A1 (0.51) ALDH1A1AGTR1KDM4ETSHRSMN1; SMN2
Hydrochloric Acid SCHEMBL5851393 0.75 GAA (0.59) ALDH1A1KDM4EGAASMN1; SMN2TAAR1
SCHEMBL5100101 0.75 TAAR1 (0.44) ALDH1A1KDM4EGAASMN1; SMN2TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1554253-A4 IMIDAZOLIUM CXCR3 INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-09-20 EP disclosed
US-20050272936-A1 Imidazolium cxcr3 inhibitors SMITHKLINE BEECHAM CORPORATION 2005-12-08 US disclosed
EP-1554253-A1 IMIDAZOLIUM CXCR3 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-07-20 EP disclosed
WO-2003101970-A1 IMIDAZOLIUM CXCR3 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272936-A1 Imidazolium cxcr3 inhibitors CXCR3, CXCR1, CCR7 ALDH1A1 1784/4885AGTR1 114/4885KDM4E 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.